Canine CD34: cloning of the cDNA and evaluation of an antiserum to recombinant protein.

Increasingly, enriched populations of hematopoietic progenitors are used in experimental and clinical transplantation studies. The separation of progenitors is based on the expression of CD34, a marker preferentially expressed on progenitor cells. The dog model has been important for preclinical transplant studies, because it has proven predictive for outcomes in human hematopoietic stem cell transplantation. To identify and isolate canine hematopoietic progenitors, we have cloned a cDNA encoding a CD34 homologue from a canine myelomonocytic leukemia cell line, ML2. The CD34 homologue cDNA predicts an amino acid sequence that is highly conserved with human and murine CD34 in the cytoplasmic domain, transmembrane domain, and C-terminal end of the extracellular domain, but shows considerable divergence from these sequences at the amino-terminal end of the protein. In Western blotting studies, canine CD34 homologue (caCD34) appears to be a heavily and variably glycosylated protein with a molecular weight of approximately 100 kD and shows some tissue-specific differences in protein mass. To evaluate the expression of caCD34 protein, the extracellular domain of caCD34 was expressed as an Ig fusion protein and used as an immunogen to generate a rabbit polyclonal antiserum. The antiserum reacted against the fusion protein, against vascular endothelium, and with three leukemic cell lines. Approximately 1% of canine bone marrow cells stained brightly with antibodies to caCD34 and this population was 25- to 50-fold enriched for colony-forming units-granulocyte-macrophage as compared to unfractionated marrow mononuclear cells. These findings suggest that the canine CD34 homologue is expressed on bone marrow progenitor cells and, thus, that this molecule should be a valuable marker for identifying and isolating canine hematopoietic progenitors for experimental hematopoiesis and stem cell transplantation.

[1]  B. Sandmaier,et al.  An antibody to CD44 enhances hematopoiesis in long-term marrow cultures. , 1996, Experimental hematology.

[2]  M. Fackler,et al.  CD34: structure, biology, and clinical utility. , 1996, Blood.

[3]  A. Lichtenstein,et al.  Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma. , 1995, Blood.

[4]  M. Fackler,et al.  Full-length but not truncated CD34 inhibits hematopoietic cell differentiation of M1 cells. , 1995, Blood.

[5]  H. Deeg,et al.  Differentiation of canine bone marrow cells with hemopoietic characteristics from an adherent stromal cell precursor. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[6]  L. Lasky,et al.  The sialomucin CD34 is expressed on hematopoietic cells and blood vessels during murine development. , 1995, Blood.

[7]  M. Fackler,et al.  Characterization of murine CD34, a marker for hematopoietic progenitor and stem cells. , 1994, Blood.

[8]  E. Shpall,et al.  Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  L. Lasky,et al.  Global vascular expression of murine CD34, a sialomucin-like endothelial ligand for L-selectin. , 1994, Blood.

[10]  S. Hemmerich,et al.  Binding of L-selectin to the vascular sialomucin CD34. , 1993, Science.

[11]  H. Nakauchi,et al.  Two alternative forms of cDNA encoding CD34. , 1993, Experimental hematology.

[12]  D. Tenen,et al.  The human CD34 hematopoietic stem cell antigen promoter and a 3' enhancer direct hematopoietic expression in tissue culture. , 1992, Blood.

[13]  P. Linsley,et al.  Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. , 1992, Science.

[14]  T. Suda,et al.  Two types of murine CD34 mRNA generated by alternative splicing. , 1992, Blood.

[15]  M. L. Beau,et al.  Structure of the gene encoding CD34, a human hematopoietic stem cell antigen. , 1992, Genomics.

[16]  I. Bernstein,et al.  Engraftment after infusion of CD34+ marrow cells in patients with breast cancer or neuroblastoma. , 1991, Blood.

[17]  F. Collins,et al.  Construction of T-vectors, a rapid and general system for direct cloning of unmodified PCR products. , 1991, Nucleic acids research.

[18]  M. Greaves,et al.  The gene encoding the stem cell antigen, CD34, is conserved in mouse and expressed in haemopoietic progenitor cell lines, brain, and embryonic fibroblasts. , 1991, International immunology.

[19]  I. Bernstein,et al.  Biochemical characterization of a unique canine myeloid antigen. , 1991, Leukemia.

[20]  M. Greaves,et al.  Expression of the CD34 gene in vascular endothelial cells. , 1990, Blood.

[21]  T. Shenk,et al.  Functional analysis of point mutations in the AAUAAA motif of the SV40 late polyadenylation signal. , 1989, Nucleic acids research.

[22]  G. Cain,et al.  Establishment and partial characterization of a radiation-induced canine monocytic leukemic cell line (RK9ML-1). , 1989, Leukemia research.

[23]  M. Greaves,et al.  Structural and partial amino acid sequence analysis of the human hemopoietic progenitor cell antigen CD34. , 1988, Leukemia.

[24]  M. Frohman,et al.  Rapid production of full-length cDNAs from rare transcripts: amplification using a single gene-specific oligonucleotide primer. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[25]  W. Huse,et al.  Lambda ZAP: a bacteriophage lambda expression vector with in vivo excision properties. , 1988, Nucleic acids research.

[26]  M. Kozak Leader length and secondary structure modulate mRNA function under conditions of stress , 1988, Molecular and cellular biology.

[27]  I. Bernstein,et al.  Antigen CD34+ marrow cells engraft lethally irradiated baboons. , 1988, The Journal of clinical investigation.

[28]  H. Deeg,et al.  FACILITATION OF ENGRAFTMENT OF DLA‐NONIDENTICAL MARROW BY TREATMENT OF RECIPIENTS WITH MONOCLONAL ANTIBODY DIRECTED AGAINST MARROW CELLS SURVIVING RADIATION , 1987, Transplantation.

[29]  R. Hoffman,et al.  Characterization of adult human marrow hematopoietic progenitors highly enriched by two-color cell sorting with My10 and major histocompatibility class II monoclonal antibodies. , 1987, Journal of immunology.

[30]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[31]  K L Gould,et al.  Substrate specificity of protein kinase C. Use of synthetic peptides corresponding to physiological sites as probes for substrate recognition requirements. , 1986, European journal of biochemistry.

[32]  C. Civin,et al.  Antigenic analysis of hematopoiesis. V. Characterization of My-10 antigen expression by normal lymphohematopoietic progenitor cells. , 1986, Experimental hematology.

[33]  G. Shaw,et al.  A conserved AU sequence from the 3′ untranslated region of GM-CSF mRNA mediates selective mRNA degradation , 1986, Cell.

[34]  R. Andrews,et al.  Monoclonal antibody 12-8 recognizes a 115-kd molecule present on both unipotent and multipotent hematopoietic colony-forming cells and their precursors. , 1986, Blood.

[35]  R. Storb,et al.  Graft‐versus‐Host Disease in Dog and Man: The Seattle Experience , 1985, Immunological reviews.

[36]  I. Bernstein,et al.  Influence of antibody isotype on passive serotherapy of lymphoma. , 1985, Journal of immunology.

[37]  M. Greaves,et al.  Identification of a membrane glycoprotein associated with haemopoietic progenitor cells. , 1985, Leukemia research.

[38]  M. Fackler,et al.  Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. , 1984, Journal of immunology.

[39]  J. Devereux,et al.  A comprehensive set of sequence analysis programs for the VAX , 1984, Nucleic Acids Res..

[40]  A. Feinberg,et al.  A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. , 1983, Analytical biochemistry.

[41]  F. Sanger,et al.  DNA sequencing with chain-terminating inhibitors. , 1977, Proceedings of the National Academy of Sciences of the United States of America.